The hallmarks of cancer, Cell, vol.100, issue.1, pp.55-70, 2000. ,
Hallmarks of cancer: the next generation. Cell, 4 Mars, pp.646-74, 2011. ,
The immunobiology of cancer immunosurveillance and immunoediting, Immunity, Aout, vol.21, pp.137-148, 2004. ,
New insights into cancer immunoediting and its three component phases?elimination, equilibrium and escape, Current Opinion in Immunology, vol.27, pp.16-65, 2014. ,
Oncology meets immunology: The cancer immunity cycle, Immunity, vol.39, issue.1, pp.1-10 ,
Adaptative immunity maintains occult cancer in an equilibrium state, Nature, vol.450, pp.903-907, 2007. ,
Advances in the understanding of cancer immunotherapy, BJU International, vol.116, pp.321-329, 2015. ,
Immune escape mechanisms as a guide for cancer immunotherapy, Clinical Cancer Research, vol.15, issue.214, pp.687-692, 2015. ,
The evolving role of immune checkpoint inhibitors in cancer treatment. The Oncologist, pp.812-822, 2015. ,
The roles of regulatory B cells in cancer, Journal of immunology research, 2014. ,
B lymphocytes as effector cells in the immunotherapy of cancer, Journal of surgical oncology, vol.105, issue.4, pp.15-2012431 ,
Myeloid derived suppressor cells ? a new therapeutic target in the treatment of cancer, Journal for immunotherapy of cancer, vol.1, pp.15-201310, 2013. ,
Signaling pathways involved in MDSC regulation, Biochimica et Biophysica Acta, vol.1846, issue.1, pp.55-65, 2014. ,
The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, pp.252-264, 2012. ,
Immune checkpoint inhibitors in clinical trials, Chinese Journal of Cancer, vol.33, issue.9, pp.434-444, 2014. ,
Immunomodulation : checkpoint blockade etc, Neuro-Oncology, vol.17, pp.26-31, 2015. ,
Development of new immunotherapy treatments in different cancer types, Journal of Medecine and Life Juillet-Septembre, vol.2016, issue.93, pp.240-248 ,
New developments in the treatment of metastatic melanoma : immune checkpoint inhibitors and targeted therapies, Anticancer Research, vol.34, issue.4, pp.1493-505, 2014. ,
CTLA-4 and PD-1 pathways: Similarities, differences and implications of their inhibition, American Journal of Clinical Oncology, vol.39, issue.1, pp.98-106, 2016. ,
Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy, Journal of Clinical Investigation, p.15 ,
Cytotoxic T Lymphocyte Antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength, Immunity, vol.16, issue.1, pp.23-35, 2002. ,
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. The Oncologist, pp.2-9, 2008. ,
Tumor-specific Th2 responses inhibit growth of CT26 colon-cancer cells in mice via converting intratumor regulatory T cells to Th9 cells Scientific Reports, pp.2-201510665 ,
The Treg/Th17 paradigm in lung cancer, Journal of immunology Research, p.730380, 2014. ,
Nuclear molecular imaging strategies in immune checkpoint inhibitor therapy, p.23, 2017. ,
Improved survival with Ipilimumab in patients with metastatic melanoma, pp.363711-723, 2010. ,
Ipilimumab in advanced melanoma : reports of long-lasting responses, Melanoma research, vol.22, issue.3, pp.263-70, 2012. ,
Immune response to cancer therapy : Mounting an effective antitumor response and mechanisms of resistance. Trends in Cancer, pp.66-75, 2015. ,
CTLA-4 blockade in tumor models : an overview of preclinical and translational research. Cancer immunity, pp.22-20135 ,
Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules, The Journal of Immunology, issue.10, pp.1845493-501, 2010. ,
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models, Cancer immunology, Immunotherapy, vol.62, pp.1533-1545, 2013. ,
Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model, Cancer Research, vol.60, pp.15-2710, 2000. ,
éthique de l'expérimentation animale, Directive n°2010/63 CEE, 22 Septembre, 2010. ,
Guide for the care and use of laboratory animals, 1996. ,
Chapter 13: Anatomy. Dans Biology of the laboratory mouse, seconde édition, 1968. ,
Transplantable Syngeneic Rodent Tumors : Solid Tumors in Mice. Dans Tumor models in cancer research, seconde edition, 2010. ,
Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma, pp.23-34, 2015. ,
The role of regulatory T cells in cancer immunology. ImmunoTargets and Therapy, pp.159-171, 2015. ,
Into the eye of the cytokine storm, Microbiology and Molecular Biology Reviews, vol.76, issue.1, pp.16-32, 2012. ,
PD-L1 detection in tumors using [ 64 Cu]Atezolizumab with PET, Bioconjugate Chemistry, vol.27, issue.9, pp.2103-2110, 2016. ,
4-1BB agonists: Multi-potent potentiators of tumor immunity, Frontiers in Oncology, issue.5, p.117, 2015. ,
Gemcitabine directly inhibits myeloid derived suppressor cells n BALB/C mice, International Immunopharmacology, vol.9, issue.78, pp.900-909, 2009. ,
Macrophages support splenic erythropoiesis in 4T1-tumor bearing mice, Plos One, issue.3, pp.10-0121921, 2015. ,
Tumor-induced MDSC act via remote control to inhibit L-selectindependent adaptive immunity in lymph nodes. eLife, p.17375, 2016. ,
Programmed death Ligand 2 in cancer-induced immune suppression, Clinical and Developmental Immunology, p.656340, 2012. ,
Targeting natural killer cells and natural killer T cells in cancer, Nature Reviews Immunology, vol.5, issue.4, pp.239-252, 2012. ,
DOI : 10.1038/nri1603
Th2-mediated anti-tumour immunity : friend of foe? Tissue Antigens, pp.1-11, 2007. ,
New immunotherapies targeting the PD-1 pathways, Trends in Pharmacological Sciences, vol.36, issue.9, pp.587-95, 2015. ,
PD-L1 expression as a predictive biomarker in cancer immunotherapy, Molecular Cancer Therapeutics, vol.14, issue.4, pp.847-56, 2015. ,
B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers and combinations, Science Translational Medicine, vol.8, issue.328, 2016. ,